ESMO 2021: PARPi data and their role in mono/combination therapies

Radioembolisation with chemotherapy for colorectal liver metastases

Amivantamab combo with lazertinib favourable in post-osimertinib EGFR-mutant NSCLC

ESMO 2021: Breast cancer roundup

[Vic-]trastuzumab duocarmazine shows improved PFS in pre-treated HER2+ locally advanced or metastatic breast cancer

Enzalutamide plus androgen deprivation therapy prolongs survival in men with metastatic hormone-sensitive prostate cancer

Acetylsalicylic acid added to atezolizumab bevacizumab combo does not improve efficacy in ovarian, fallopian, peritoneal cancer

Drug combination shows promise in treatment-resistant advanced ovarian cancer

Assessment of guideline adherence in breast cancer management among oncologists in Nigeria

Challenges in first line ALK+ NSCLC and emerging data on ALK TKIs

Safety of sotorasib and panitumumab in advanced KRAS p.G12C-mutated colorectal cancer

Adding abiraterone acetate plus prednisolone to standard therapy lengthens survival in non-metastatic high-risk prostate cancer